HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (3- fluoro- 4- hydroxyphenyl)- 7- hydroxy- 1- naphthonitrile

structure in first source

Also Known As:

WAY 202196; WAY-202196; WAY202196

Networked: 2 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Naphthols: 64
        3-(3-fluoro-4-hydroxyphenyl)-7-hydroxy-1-naphthonitrile: 2
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Naphthols: 64
      - 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxy-1-naphthonitrile: 2

Experts

1.	Harris, Heather A: 2 articles (08/2006 - 06/2005)
2.	Keith, James C: 2 articles (08/2006 - 06/2005)
3.	Cristofaro, Patricia A: 1 article (08/2006)
4.	Jhung, Jhung: 1 article (08/2006)
5.	Opal, Steven M: 1 article (08/2006)
6.	Palardy, John E: 1 article (08/2006)
7.	Parejo, Nicolas A: 1 article (08/2006)
8.	Edsall, Richard J: 1 article (06/2005)
9.	Henderson, Ruth A: 1 article (06/2005)
10.	Manas, Eric S: 1 article (06/2005)

Related Diseases

1.	Inflammation (Inflammations) 06/16/2005 - "One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases." 08/01/2006 - "These results indicate that oral administration of WAY-202196 preserved gastrointestinal barrier function and improved outcome in experimental models of systemic infection and inflammation. "
2.	Sepsis (Septicemia) 08/01/2006 - "WAY-202196 and similar agents may prove useful clinically as a novel treatment strategy for the treatment or prevention of severe sepsis." 08/01/2006 - "WAY-202196, a nonsteroidal selective estrogen receptor-beta agonist, was tested in the murine listeriosis model, the neutropenic rat Pseudomonas aeruginosa infection, and the mouse cecal ligation and puncture sepsis models. "
3.	Bacteremia 08/01/2006 - "Similar results were obtained in a cecal ligation and puncture model, in which multiple oral doses of WAY-202196 (50 mg/kg) improved survival (83% vs. 0%; p < 0.05), preserved intestinal epithelial integrity, and significantly reduced systemic bacteremia and peritoneal interleukin-6 and tumor necrosis factor levels. "
4.	Infections 08/01/2006 - "These results indicate that oral administration of WAY-202196 preserved gastrointestinal barrier function and improved outcome in experimental models of systemic infection and inflammation. "
5.	Septic Shock (Toxic Shock Syndrome) 08/01/2006 - "WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock."

Related Drugs and Biologics

1.	Interleukin-6 (Interleukin 6)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Estrogen Receptor beta

Related Therapies and Procedures

1.	Punctures
2.	Ligation
3.	Oral Administration